In advanced bladder cancer, a phase II clinical trial is studying the efficacy and safety of erdafitinib in combination with a sensitive cytochrome 450 (CYP) 3A substrate (midazolam) and with an organic cation transporter 2 (OCT2) probe substrate (metformin). Here, SLC22A2 is linked to urinary bladder carcinoma.